M&A Deal Summary |
|
|---|---|
| Date | 2015-05-06 |
| Target | Epitherapeutics ApS |
| Sector | Life Science |
| Buyer(s) | Gilead Sciences |
| Deal Type | Add-on Acquisition |
| Deal Value | 65M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1987 |
| Sector | Life Science |
| Employees | 17,600 |
| Revenue | 28.8B USD (2024) |
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded in 1987 and is Based in Foster City, California.
| DEAL STATS | # |
|---|---|
| Overall | 14 of 24 |
| Sector: Life Science M&A | 13 of 23 |
| Type: Add-on Acquisition M&A Deals | 12 of 20 |
| Country: Denmark M&A | 1 of 1 |
| Year: 2015 M&A | 2 of 2 |
| Size (of disclosed) | 20 of 21 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-01-06 |
Phenex Pharmaceuticals AG
Ludwigshafen, Germany Phenex Pharmaceuticals is a drug discovery and development company focused on the target class of nuclear receptors for the development of novel pharmaceuticals. |
Buy | $470M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-04-04 |
Nimbus Apollo
United States Nimbus Apollo program includes the lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases. |
Buy | $400M |
